← Leaderboards
Rongfu Wang
University Of Southern California
$19,053,396
Attributed
$19,861,154
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,861,154 · 11
By mechanism
R01$15,657,454 · 7
P50$1,713,297 · 1
P01$1,359,811 · 1
U54$1,048,497 · 1
P30$82,095 · 1
Top collaborators
- Frank M Orson5 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Pin Wang$5,634,307
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsAntigensImmune ResponseTumorImmunityMediatingCellsBaseTumor AntigensT-LymphocyteResponseCancer ImmunotherapyNeoplastic CellPlayPeptidesCytokineVaccinesCd8b1 GeneCancer PatientIn VivoCancer VaccinesImmuneSignal PathwayLaboratories
Grant awards (64)
Lung Cancer Immunotherapy using new generation of TCR-engineered CD4 + T cells$650,450
R01 · FY2025 · CA · contact PI
CD4+ T cells and neoantigens in melanoma immunotherapy.$640,273
R01 · FY2025 · CA · contact PI
CD4+ T cells and neoantigens in melanoma immunotherapy.$608,260
R01 · FY2024 · CA · contact PI
CD4+ T cells and neoantigens in melanoma immunotherapy.$627,467
R01 · FY2023 · CA · contact PI
CD4+ T cells and neoantigens in melanoma immunotherapy.$627,467
R01 · FY2022 · CA · contact PI
Novel Strategies for Intervention of Inflammatory Diseases and Cancer$307,230
R01 · FY2022 · CA · contact PI
Tumor Microenvironment$82,095
P30 · FY2022 · CA · contact PI
CD4+ T cells and neoantigens in melanoma immunotherapy.$640,273
R01 · FY2021 · CA · contact PI
Novel Strategies for Intervention of Inflammatory Diseases and Cancer$313,500
R01 · FY2021 · CA · contact PI
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$446,417
U54 · FY2020 · CA · contact PI
NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER$313,500
R01 · FY2020 · CA · contact PI
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$161,500
U54 · FY2020 · CA · contact PI
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$440,580
U54 · FY2019 · CA · contact PI
Novel Strategies for Intervention of Inflammatory Diseases and Cancer - Research Supplement to R01-CA101795$403,677
R01 · FY2019 · CA · contact PI
Novel Strategies for Intervention of Inflammatory Diseases and Cancer$297,644
R01 · FY2019 · CA · contact PI
Novel Strategies for Intervention of Inflammatory Diseases and Cancer$306,850
R01 · FY2018 · CA · contact PI
Novel Strategies for Immunotherapy of Cancer$272,032
R01 · FY2015 · CA · contact PI
Development of Novel Vaccines for Cocaine Abuse$287,574
R01 · FY2014 · DA · contact PI
Novel Strategies for Immunotherapy of Cancer$263,871
R01 · FY2014 · CA · contact PI
The Role of CD4+ T Cells in Antitumor Immunity$285,569
R01 · FY2013 · CA · contact PI
Development of Novel Vaccines for Cocaine Abuse$277,071
R01 · FY2013 · DA · contact PI
Novel Strategies for Immunotherapy of Cancer$255,710
R01 · FY2013 · CA · contact PI
The Role of CD4+ T Cells in Antitumor Immunity$303,797
R01 · FY2012 · CA · contact PI
Development of Novel Vaccines for Cocaine Abuse$286,358
R01 · FY2012 · DA · contact PI
Novel Strategies for Immunotherapy of Cancer$272,032
R01 · FY2012 · CA · contact PI
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY$267,343
P01 · FY2012 · CA · contact PI
Development of Novel Vaccines for Cocaine Abuse$379,513
R01 · FY2011 · DA · contact PI
The Role of CD4+ T Cells in Antitumor Immunity$299,889
R01 · FY2011 · CA · contact PI
Novel Strategies for Immunotherapy of Cancer$272,032
R01 · FY2011 · CA · contact PI
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY$269,219
P01 · FY2011 · CA · contact PI
Development of Novel Vaccines for Cocaine Abuse$385,000
R01 · FY2010 · DA · contact PI
The Role of CD4+ T Cells in Antitumor Immunity$309,164
R01 · FY2010 · CA · contact PI
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY$279,400
P01 · FY2010 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$148,053
R01 · FY2010 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$137,314
R01 · FY2010 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$125,660
R01 · FY2010 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$114,527
R01 · FY2010 · CA · contact PI
The Role of CD4+ T Cells in Antitumor Immunity$309,164
R01 · FY2009 · CA · contact PI
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY$275,795
P01 · FY2009 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$258,529
R01 · FY2009 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$258,529
R01 · FY2009 · CA · contact PI
HLA II PRESENTATION OF ANTIGENS FOR VACCINE$410,571
P50 · FY2008 · CA · contact PI
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY$268,054
P01 · FY2008 · CA · contact PI
Novel Strategies for Immunotherapy of Cancer$263,284
R01 · FY2008 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$258,529
R01 · FY2008 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$258,529
R01 · FY2008 · CA · contact PI
HLA II PRESENTATION OF ANTIGENS FOR VACCINE$422,289
P50 · FY2007 · CA · contact PI
Novel Strategies for Immunotherapy of Cancer$263,284
R01 · FY2007 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$258,529
R01 · FY2007 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$258,529
R01 · FY2007 · CA · contact PI
MHC Class II Restricted Tumor Antigens and CD4+T Cells$294,294
R01 · FY2006 · CA · contact PI
HLA II PRESENTATION OF ANTIGENS FOR VACCINE$293,479
P50 · FY2006 · CA · contact PI
Novel Strategies for Immunotherapy fo Cancer$271,147
R01 · FY2006 · CA · contact PI
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell$266,250
R01 · FY2006 · CA · contact PI
Reversal of regulatory T cell function in prostate cancer$266,250
R01 · FY2006 · CA · contact PI
MHC Class II Restricted Tumor Antigens and CD4+T Cells$301,376
R01 · FY2005 · CA
HLA II PRESENTATION OF ANTIGENS FOR VACCINE$293,479
P50 · FY2005 · CA
Novel Strategies for Immunotherapy fo Cancer$277,673
R01 · FY2005 · CA
MHC Class II Restricted Tumor Antigens and CD4+T Cells$301,376
R01 · FY2004 · CA
HLA II PRESENTATION OF ANTIGENS FOR VACCINE$293,479
P50 · FY2004 · CA
Novel Strategies for Immunotherapy of Cancer$277,673
R01 · FY2004 · CA
MHC Class II Restricted Tumor Antigens and CD4+T Cells$301,376
R01 · FY2003 · CA
MHC Class II Restricted Tumor Antigens and CD4+T Cells$301,376
R01 · FY2002 · CA
MHC Class II Restricted EBV Peptides and CD4 T Cells in Cancer Immunotherapy$0
P01 · FY2002 · CA